COHANCE - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 2.1
Show all parameters (20 more)
🧾 Trade Setup
Buy at 435 ₹. Initial stop-loss level at 420 ₹ – protect against immediate selling pressure stemming from the stake sale announcement. A profit target should be set at 455 ₹, taking into account the current strong volume and potential for a short-term rebound driven by broader market sentiment or positive investor sentiment regarding the USFDA findings (although this is highly unlikely to immediately resolve the inspection issues). Overall, this trade is HIGHLY risky due to the negative news catalyst.
✅ Positive
Immediate volume is strong at 12.2M, indicating significant interest today. The RSI of 47 suggests the stock is relatively undervalued compared to its recent high and shows potential for a bounce given it’s currently approaching its 200-day moving average.
⚠️ Limitation
The promoters releasing a large stake encumbrance (57.49%) is a major red flag, likely triggering significant selling pressure. Furthermore, the USFDA inspection resulting in a Form 483 with observations represents a substantial risk to future earnings and could trigger a sharp downward correction.
📉 Company Negative News
The USFDA inspection findings are concerning and could lead to production delays or import restrictions impacting revenue projections.
🏭 Industry
The pharmaceutical sector is currently facing regulatory scrutiny, with several companies experiencing volatility due to FDA inspections and potential supply chain issues. Despite this broader caution, the industry remains generally resilient, and momentum is expected in certain specialty drug segments.